Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Pentenero M.;
2020

Abstract

Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.
126
19
4423
4431
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33100
cancer; gastrointestinal; guidelines; mucositis; Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO); oral
Elad S.; Cheng K.K.F.; Lalla R.V.; Yarom N.; Hong C.; Logan R.M.; Bowen J.; Gibson R.; Saunders D.P.; Zadik Y.; Ariyawardana A.; Correa M.E.; Ranna V.; Bossi P.; Arany P.; Al-Azri A.R.; Blijlevens N.; Hovan A.; Fregnani E.; Fulton J.; Gueiros L.A.; Rouleau T.; Coller J.K.; Al-Dasooqi N.; Wardill H.; Ameringer S.; Antunes H.S.; Bateman E.H.; Bektas K.; Bensadoun R.-J.; Ten Bohmer K.; Brito-Dellan N.; Castillo D.; Chiang K.; de Mooij C.; Eilers J.; Epstein J.; Galiti D.; Fall-Dickson J.M.; Gobbo M.; Issa Hazboun H.; Jensen S.B.; Johansen J.; Joy J.; Joy K.; Kandwal A.; Kataoka T.; Keefe D.; Loprinzi C.L.; Lubart R.; Skripnik Lucas A.; Majorana A.; Mayo B.; de Mooij C.; Mori T.; Nair R.G.; Nasr N.; Nicolatou-Galitis O.; Ottaviani G.; Migliorati C.; Pentenero M.; Porcello L.; Peterson D.; Potting C.; Raber-Durlacher J.; van Sebille Y.Z.A.; Soga Y.; Sonis S.; Stringer A.M.; Thorpe D.; Tilly V.; Tissing W.; Toro J.J.; Treister N.S.; Vaddi A.; Weikel D.; van de Wetering M.; Zur E.
File in questo prodotto:
File Dimensione Formato  
Elad-2020-MASCC_ISOO clinical practice guideli.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 143.88 kB
Formato Adobe PDF
143.88 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1782720
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 96
  • ???jsp.display-item.citation.isi??? 78
social impact